Overview

Tabula Bioscience uses machine learning to improve disease prediction and personalized medicine. Its core product aims to design programmable, strain-specific antimicrobials that target bacteria via bacteriophages, with R&D focused on phage therapy and gram-negative bacteria. The models leverage unlabeled genomic data from humans and other species, incorporate expert priors and epigenetic information, and use probabilistic programming to build mechanistic biological explanations. The goal is to narrow the gap between heritability and prediction to enable more effective, individualized treatments.